PuSH - Publication Server of Helmholtz Zentrum München

Steinbeis, F.* ; Thibeault, C.* ; Steinbrecher, S.* ; Ahlgrimm, Y.* ; Haack, I.A.* ; August, D.* ; Balzuweit, B.* ; Bellinghausen, C.* ; Berger, S.* ; Chaplinskaya-Sobol, I.* ; Cornely, O.* ; Doeblin, P.* ; Endres, M.* ; Fink, C.* ; Finke, C.* ; Frank, S.* ; Hans, S.* ; Hartung, T.* ; Hellmuth, J.C.* ; Herold, S.* ; Heuschmann, P.* ; Heyckendorf, J.* ; Heyder, R.* ; Hippenstiel, S.* ; Hoffmann, W.* ; Kelle, S.U.* ; Knape, P.* ; Koehler, P.* ; Kretzler, L.* ; Leistner, D.M.* ; Lienau, J.* ; Lorbeer, R.* ; Lorenz-Depiereux, B. ; Lüttke, C.D.* ; Mai, K.* ; Merle, U.* ; Meyer-Arndt, L.A.* ; Miljukov, O.* ; Muenchhoff, M.* ; Müller-Plathe, M.* ; Neuhann, J.* ; Neuhauser, H.* ; Nieters, A.* ; Otte, C.* ; Pape, D.* ; Pinto, R.M.* ; Pley, C.* ; Pudszuhn, A.* ; Reuken, P.* ; Rieg, S.* ; Ritter, P.* ; Rohde, G.* ; Rönnefarth, M.* ; Ruzicka, M.* ; Schaller, J.* ; Schmidt, A.* ; Schmidt, S.* ; Schwachmeyer, V.* ; Schwanitz, G.* ; Seeger, W.* ; Stahl, D.* ; Stobäus, N.* ; Stubbe, H.C.* ; Suttorp, N.* ; Temmesfeld, B.* ; Thun, S.* ; Triller, P.* ; Trinkmann, F.* ; Vadász, I.* ; Valentin, H.* ; Vehreschild, M.* ; von Kalle, C.* ; von Lilienfeld-Toal, M.* ; Weber, J.* ; Welte, T.* ; Wildberg, C.* ; Wizimirski, R.* ; Zvork, S.* ; Sander, L.E.* ; Vehreschild, J.* ; Zöller, T.* ; Kurth, F.* ; Witzenrath, M.*

Analysis of acute COVID-19 including chronic morbidity: Protocol for the deep phenotyping National Pandemic Cohort Network in Germany (NAPKON-HAP).

Infection:12 (2023)
Publ. Version/Full Text DOI PMC
Open Access Gold (Paid Option)
Creative Commons Lizenzvertrag
BACKGROUND: The severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) pandemic causes a high burden of acute and long-term morbidity and mortality worldwide despite global efforts in containment, prophylaxis, and therapy. With unprecedented speed, the global scientific community has generated pivotal insights into the pathogen and the host response evoked by the infection. However, deeper characterization of the pathophysiology and pathology remains a high priority to reduce morbidity and mortality of coronavirus disease 2019 (COVID-19). METHODS: NAPKON-HAP is a multi-centered prospective observational study with a long-term follow-up phase of up to 36 months post-SARS-CoV-2 infection. It constitutes a central platform for harmonized data and biospecimen for interdisciplinary characterization of acute SARS-CoV-2 infection and long-term outcomes of diverging disease severities of hospitalized patients. RESULTS: Primary outcome measures include clinical scores and quality of life assessment captured during hospitalization and at outpatient follow-up visits to assess acute and chronic morbidity. Secondary measures include results of biomolecular and immunological investigations and assessment of organ-specific involvement during and post-COVID-19 infection. NAPKON-HAP constitutes a national platform to provide accessibility and usability of the comprehensive data and biospecimen collection to global research. CONCLUSION: NAPKON-HAP establishes a platform with standardized high-resolution data and biospecimen collection of hospitalized COVID-19 patients of different disease severities in Germany. With this study, we will add significant scientific insights and provide high-quality data to aid researchers to investigate COVID-19 pathophysiology, pathology, and chronic morbidity.
Altmetric
Additional Metrics?
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Corresponding Author
Keywords Covid-19 ; Coronavirus ; Deep Phenotyping ; Infectious Disease ; Sars-cov-2
ISSN (print) / ISBN 0300-8126
e-ISSN 1439-0973
Quellenangaben Volume: , Issue: , Pages: , Article Number: 12 Supplement: ,
Publisher Urban & Vogel
Publishing Place Tiergartenstrasse 17, D-69121 Heidelberg, Germany
Non-patent literature Publications
Reviewing status Peer reviewed
Grants German Federal Ministry of Education and Research (BMBF)
National Pandemic Cohort Network (NAPKON) is part of the Network University Medicine (NUM)
Projekt DEAL